Somerset Group LLC purchased a new position in shares of Solventum Co. (NYSE:SOLV – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,456 shares of the company’s stock, valued at approximately $764,000.
A number of other large investors also recently bought and sold shares of SOLV. Davis Selected Advisers purchased a new stake in shares of Solventum during the 2nd quarter valued at $273,070,000. Nuance Investments LLC acquired a new position in Solventum in the second quarter valued at $115,829,000. Bank of New York Mellon Corp purchased a new stake in Solventum during the second quarter valued at about $48,487,000. Hsbc Holdings PLC acquired a new stake in Solventum during the second quarter worth about $31,876,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Solventum in the 2nd quarter worth about $26,480,000.
Solventum Stock Performance
Shares of SOLV stock opened at $72.13 on Thursday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90. The company has a fifty day moving average price of $60.13.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. BTIG Research began coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating for the company. Bank of America decreased their price objective on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research note on Tuesday, June 25th. Morgan Stanley cut their target price on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Argus began coverage on shares of Solventum in a research report on Monday, June 24th. They set a “hold” rating for the company. Finally, Wells Fargo & Company cut their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. According to data from MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus target price of $58.25.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Further Reading
- Five stocks we like better than Solventum
- How to Use the MarketBeat Dividend Calculator
- Spread Your Bets: Winning the AI Race With Energy ETFs
- Quiet Period Expirations Explained
- Intuitive Machines Soars: NASA Contract Fuels Lunar Ambitions
- What is the Hang Seng index?
- 3 Beaten-Down Stocks Ready for a Comeback
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.